Potential applications of CRISPR/Cas for next-generation biomonitoring of harmful algae blooms: A review

• Published in: Harmful algae 2021-03, Vol.103, p.102027-102027, Article 102027
• Main Authors: Durán-Vinet, B, Araya-Castro, K, Chao, TC, Wood, SA, Gallardo, V, Godoy, K, Abanto, M
• Format: Article
• Language: English
• Subjects: Biomonitoring; CRISPR/Cas systems; Environmental DNA; Environmental RNA; HABs
• ISSN: 1568-9883; 1878-1470
• DOI: 10.1016/j.hal.2021.102027

•Current molecular methods have enhanced HABs/CHABs biomonitoring but have limitations.•CRISPR/Cas is a powerful and ultrasensitive molecular tool for molecular diagnosis.•Cas12/Cas13 effectors have potential as next-generation biomonitoring tools.•Multiple genes in bloom forming species could be targetted for CRISPR/Cas-based biomonitoring. Research on harmful algal and cyanobacterial blooms (HABs and CHABs) has risen dramatically due to their increasing global distribution, frequency, and intensity. These blooms jeopardize public health, ecosystem function, sustainability and can have negative economic impacts. Numerous monitoring programs have been established using light microscopy, liquid chromatography coupled to mass spectrometry (LC-MS), ELISA, and spectrophotometry to monitor HABs/CHABs outbreaks. Recently, DNA/RNA-based molecular methods have been integrated into these programs to replace or complement traditional methods through analyzing environmental DNA and RNA (eDNA/eRNA) with techniques such as quantitative polymerase chain reaction (qPCR), fluorescent in situ hybridization (FISH), sandwich hybridization assay (SHA), isothermal amplification methods, and microarrays. These have enabled the detection of rare or cryptic species, enhanced sample throughput, and reduced costs and the need for visual taxonomic expertise. However, these methods have limitations, such as the need for high capital investment in equipment or detection uncertainties, including determining whether organisms are viable. In this review, we discuss the potential of newly developed molecular diagnosis technology based on Clustered Regularly Interspaced Short Palindromic Repeats/Cas proteins (CRISPR/Cas), which utilizes the prokaryotic adaptative immune systems of bacteria and archaea. Cas12 and Cas13-based platforms can detect both DNA and RNA with attomolar sensitivity within an hour. CRISPR/Cas diagnostic is a rapid, inexpensive, specific, and ultrasensitive technology that, with some further development, will provide many new platforms that can be used for HABs/CHABs biomonitoring and research. [Display omitted]